The inclusion criteria: (1) Any clinical trials that included patients who suffered from NVAF with high stroke or bleeding risk and had undergone LAAC with Watchman device or ACP/Amulet device; (2) Studies reported any of ...
? 2024 The Authors.BACKGROUND: Long-Term outcomes following left atrial appendage occlusion outside clinical trials and small registries are largely unknown. Collecting these data was a condition of US market authorization of the WATCHMAN device. The aim of this analysis was to evaluate the rates ...
(NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage – the area of the heart where stroke-causing blood clots commonly form. This technology, which is built upon the most studied and implanted LAAC device in the world, features a...
Based on the robust WATCHMAN clinical program which consists of numerous studies, with more than 2,400 patients and nearly 6,000 patient-years of follow-up, the WATCHMAN LAAC Device is approved by FDA. In this article we reviewed the preclinical studies and clinical trials, as well as the ...
Clinical Trials in LAAC 1.PINNACLE FLX - Protection against Embolism for non-valvular AF Patients: Investigational Device Evaluation of the WATCHMAN FLX LAA Closure Technology 2.OPTION trial – Comparison of Anticoagulation with Left Atrial Appendage Closure after AF ablation ...
(1). Recently, the next-generation LAAC device, the Watchman FLX system, became available, and showed a low incidence of adverse events and a high incidence of anatomic closure (2). This transcatheter stroke prevention ha...
Medical Device Industry Landscape In Asia-Pacific GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and ...
The Watchman (Boston Scientific, MA) is a percutaneous left atrial appendage closure (LAAC) device which has been tested prospectively in multiple randomized trials. It offers a new stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation who are seeking an ...
The WATCHMAN FLX Pro device is currently being studied in the WATCHMAN FLX Pro CT study, a single-center premarket study using multiple imaging modalities to assess post-procedural device tissue coverage and the relationship, if any, to clinical outcomes. It will also be further evaluated in the...
The world's most studied and implanted LAAC device View real-world and clinical data Learn more about WATCHMAN Access resources Access WATCHMAN resources in the referring HCP download center Visit the download center Stay connected Receive monthly updates about the WATCHMAN Implant ...